Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions
Cancer of Rectum
Interventions
DRUG

combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)

To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.

Trial Locations (5)

08701

RECRUITING

RWJBarnabas Health - Monmouth Medical Center, Lakewood

07039

RECRUITING

RWJBarnabas Health - Saint Barnabas Medical Center, Livingston, Livingston

08901

RECRUITING

Rutgers, The State University of New Jersey, New Brunswick

08873

RECRUITING

RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset, Somerset

08755

RECRUITING

RWJBarnabas Health - Community Medical Center, Toms River

All Listed Sponsors
lead

Rutgers, The State University of New Jersey

OTHER